Elisabeta Benea *, V. Benea *
* Elisabeta Benea, medic primar, șef de secție, asistent universitar la Clinica I de Boli infecțioase a Spitalului Colentina, U.M.F. “Carol Davila”, București
** Dr. V. Benea, medic primar, cercetător științific gr. II la Centrul Dermatovenerologic, Spitalul Clinic de Dermatologie “Prof. S. Longhin”, București
Abstract
Antiretroviral therapy of HIV has been improved allowing better control of the disease in the last years. Apart from reverse-transcriptase inhibitors, a new class of antiretroviral drugs, protease inhibitors, has become available and offer new ways of attacking the virus. However, prolonged clinical use of the drugs currently avai lable is limited due to high toxicity, the need for concomitant medication (which may affect both efficac and toxicity), clinical events, viral and cellular resistance and therapeutic failure.